Therefore, given the key role for IL-1β as a mediator of innate immunity and the effects of interleukin inhibition in experimental atherosclerosis, interventions to reduce inflammation through IL-1β have been proposed to treat atherosclerosis. The gene discussed is IL1B; the disease is atherosclerosis.